Advertisement


Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

2024 ASCO Annual Meeting

Advertisement

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Obesity has been identified to be a risk factor for endometrial cancer, but trends overtime have not been well studied. So the objective of our study was to study the trends of endometrial cancer and obesity from 2001 to 2018 in the United States using a large national database. Additionally, we aim to identify people most at risk based on these findings and identify disparities on a population-based level. For this study, we used the United States Cancer Statistics Database to gather data on endometrial cancer. This database represents over 99% of all cancer cases diagnosed in the United States. We then performed a correction for hysterectomy and pregnancy within this database. For data on obesity, we used the NHANES database, which provides population-based statistics on obesity for the United States. To compare the relationship in trends between endometrial adenocarcinoma and obesity, a Pearson correlation coefficient was calculated for selected groups. We identified 586,000 cases of endometrioid adenocarcinoma from 2001 to 2018. When looking at our obesity data, the majority of the US female population is either overweight or obese. And the majority of Black and Hispanic women are overweight or obese. Endometrioid adenocarcinoma rates are increasing in younger age groups. In the 20 to 29 year old age group, we found that there's been a 137% increase in the rate of endometrial adenocarcinoma since 2001. In the 30 to 39 year old age group, we found that there's been a 71% increase. When looking at trends by race and ethnicity, we found that in Black women, there's been an increase in endometrial cancers of 25% since 2001, and in Hispanic women, there's been an increase of 17%. We then performed a trend analysis of obesity and endometrial cancer in parallel. Rates of obesity are rising at 7.5% in the 20 to 29 year old age group per year. The highest rate of increase in any age group. Rates of endometrial cancer are rising in this age group at 4.5% per year, also the highest of any age group. The correlation coefficient for this age group was 0.78, demonstrating a strong correlation. We see a similar trend in women age 30 to 39 with rates of obesity rising at 4.5% annually, and rates of cancer rising at 3% per year. Again, demonstrating a strong correlation with an R of 0.88. We see similar trends when we look at race and ethnicity, where obesity and endometrioid adenocarcinoma are statistically significantly correlated. In conclusion, the current data, although retrospective, demonstrate a strong temporal association in the rising rates of obesity and endometrioid adenocarcinoma in the United States. This represents a public health emergency, and actions are needed to address the impact of obesity on endometrial cancer. These actions can include increased awareness, medications, targeting weight management, surgical management of obesity, and increased research in this area.

Related Videos

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).

Breast Cancer

Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus fulvestrant, following disease progression in patients with hormone receptor–positive, HER2-negative advanced breast cancer (LBA1001).

Leukemia
Immunotherapy

Allison M. Winter, MD, on Richter Transformation: New Data on a CAR T-Cell Treatment

Allison M. Winter, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses real-world outcomes with lisocabtagene maraleucel in patients with Richter transformation, a difficult-to-treat population with a poor prognosis. Data from the Center for International Blood and Marrow Transplant Research showed this therapy provided clinical benefit with a high complete response rate (Abstract 7010).

Colorectal Cancer

Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone

Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).

Lung Cancer

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).

Advertisement

Advertisement




Advertisement